Anti-IDH2 Antibody Picoband® (monoclonal, 6B13)

Overview

Anti-IDH2 Antibody Picoband® (monoclonal, 6B13) is an antibody for IDH2 detection raised in Mouse (Monoclonal, clone Clone: 6B13, Mouse IgG2a), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, IF, ICC, Flow Cytometry, ELISA workflows.

Key elements and design rationale

• Target: IDH2 (CD5 molecule); UniProt: P48735
• Antibody format: Mouse, Monoclonal, clone Clone: 6B13, Mouse IgG2a
• Molecular weight: 45 kDa
• Applications: WB, IHC, IF, ICC, Flow Cytometry, ELISA

Vendor description (summary): Boster Bio Anti-IDH2 Antibody Picoband® (monoclonal, 6B13) catalog # M00510-4.

Biological background

Biological context: May act as a receptor in regulating T-cell proliferation.

Expression and localization notes: cellular localization: Cell membrane; Single-pass type I membrane protein, tissue context: Brain, liver, placenta, lymphocytes and erythrocytes..

Common research applications

• Western blotting (WB): Compare IDH2 levels across samples and conditions using appropriate loading and biological controls.
• Immunohistochemistry (IHC): Evaluate spatial distribution of IDH2 in tissue sections, considering fixation and antigen retrieval effects.
• Immunofluorescence / ICC: Assess subcellular localization patterns and co-localization with compartment markers in cultured cells.
• Flow cytometry: Quantify IDH2-positive populations in single-cell suspensions with appropriate gating and controls.
• ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.

Notes for experimental interpretation

• Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
• Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.

Additional product notes (from provided fields)

• Background: Isocitrate dehydrogenase [NADP], mitochondrialis anenzymethat in humans is encoded by theIDH2gene. Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD (+) as the electron acceptor and the other NADP (+). Five isocitrate dehydrogenases have been reported: three NAD (+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP (+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP (+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP (+)-dependent isocitrate dehydrogenase found in the mitochondria. It plays a role in intermediary metabolism and energy production. This protein may tightly associate or interact with the pyruvate dehydrogenase complex. Alternative splicing results in multiple transcript variants.
• Cross reactivity: No cross-reactivity with other proteins.
• Cellular localization: Cell membrane; Single-pass type I membrane protein
• Tissue details: Brain, liver, placenta, lymphocytes and erythrocytes.
• Research category: Cell Adhesion,Cell Type Markers,Cytoskeleton/ECM,Hematopoietic Progenitors,Immunology,Integrins,Myeloid,Signal Transduction,Stem Cells

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.